Skip to main content
All lobbying filings

TODD STRATEGY GROUP

TODD STRATEGY GROUP filed a Q2 report for PFIZER INC. on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for PFIZER INC. · Biopharmaceutical company.

All filings by TODD STRATEGY GROUP · Everything PFIZER INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • NICHOLAS UEHLECKE
    Previously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
  • NICOLAS MAGALLANES
    Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Pharmacy

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.

Tariff (miscellaneous tariff bills)

Issues related to tariff and trade policy. International Supply Chain.

Trade (domestic/foreign)

Issues related to tariff and trade policy.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem